Company intelligence / Profile preview

Talphera

San Mateo, California, United Statestalphera.com ↗
Ownership
Public · TLPH
Employees
~14
Development stage
Commercial
01

Overview

Talphera’s lead product candidate is Niyad, a lyophilized formulation of nafamostat as an anticoagulant for extracorporeal circuits in dialysis. Other pipeline assets include LTX‑608 for inflammatory and viral conditions, and ready-to-use prefilled syringes such as PFS‑02 and Fedsyra targeting hypotension and clotting disorders. The company divested its FDA-approved acute pain drug DSUVIA in 2023 but retains royalty rights on future sales[1][3][4].

Therapeutic areas
GastroenterologyPulmonologyCardiovascularHematologyInfectious Diseases
Modalities
Small moleculeDevice (prefilled syringe products)
Industry
Biotech
02

Drug pipeline

11 assets

sufentanil

Approved

10 more assets in the full pipeline.

03

Partnerships

none disclosed post-rebranding; previously partnered with Alora Pharmaceuticals via DSUVIA divestment[1]
04

Financials

Market cap
$52.4M
Total revenue
$28K
Enterprise value
$35.3M

Beyond the preview

Go deeper on Talphera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talphera.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call